Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Other Accumulated Expenses: 2019-2025

Historic Other Accumulated Expenses for BridgeBio Pharma (BBIO) over the last 7 years, with Sep 2025 value amounting to $92.7 million.

  • BridgeBio Pharma's Other Accumulated Expenses rose 615.83% to $92.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $92.7 million, marking a year-over-year increase of 615.83%. This contributed to the annual value of $33.1 million for FY2024, which is 610.14% up from last year.
  • As of Q3 2025, BridgeBio Pharma's Other Accumulated Expenses stood at $92.7 million, which was up 40.70% from $65.9 million recorded in Q2 2025.
  • BridgeBio Pharma's Other Accumulated Expenses' 5-year high stood at $92.7 million during Q3 2025, with a 5-year trough of $4.7 million in Q4 2023.
  • For the 3-year period, BridgeBio Pharma's Other Accumulated Expenses averaged around $29.8 million, with its median value being $17.6 million (2023).
  • In the last 5 years, BridgeBio Pharma's Other Accumulated Expenses tumbled by 82.86% in 2022 and then skyrocketed by 628.51% in 2025.
  • Quarterly analysis of 5 years shows BridgeBio Pharma's Other Accumulated Expenses stood at $30.3 million in 2021, then tumbled by 82.86% to $5.2 million in 2022, then fell by 10.27% to $4.7 million in 2023, then surged by 610.14% to $33.1 million in 2024, then skyrocketed by 615.83% to $92.7 million in 2025.
  • Its Other Accumulated Expenses stands at $92.7 million for Q3 2025, versus $65.9 million for Q2 2025 and $40.7 million for Q1 2025.